Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

Marc HumbertCamille TailléLaurence MalaVincent Le GrosJocelyne JustMathieu Molimard

Abstract

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.

This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate and a combination of both. Response rate was calculated according to blood eosinophil count measured in the year prior to omalizumab initiation.

872 SAA omalizumab-treated patients were included by 78 physicians (723 adults (age ≥18 years) and 149 minors (age 6–17 years)). Blood eosinophil count was ≥300 cells·µL−1 in 52.1% of adults and 73.8% of minors. By physician evaluation, 67.2% of adults and 77.2% of minors were responders and 71.1% adults and 78.5% minors had a ≥40% reduction in the exacerbation rate. In adults, the response rate for combined criteria was 58.4% (95% CI 53.2–63.4%) for blood eosinophils ≥300 cells·µL−1 (n=377) and 58.1% (95% CI 52.7–63.4%) for blood eosinophils <300 cells·µL−1 (n=346).

This study shows that a large proportion of patients with SAA have a blood eosinophil count ≥300 cells·µL−1, and suggests that omalizumab effectiveness is similar in “high” and “low” eosinophil subgroups.


Full Text (PDF)

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @worldallergy: WAO proudly recognizes the Asthma Center & Allergy Unit from Verona University Hospital as a WAO Center of Excellence. W…
1hreplyretweetfavorite
Interasma RT @Aller_MD: Study illustrates how neutrophils contribute to healthy tissue function https://t.co/doRA1gvlew
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergy, Asthma & Immunology! https://t.co/egpubiQAcX Thanks to @AllergyReliefNY @ChildrensMercy @AllergyUK1 #asth
1hreplyretweetfavorite
Interasma RT @Aller_MD: The latest Allergists on Social Media! https://t.co/lIEAWQXcqT
1hreplyretweetfavorite
Interasma RT @Aller_MD: Test predicts outcome of allergic rhinitis immunotherapy: researchers investigated the processes taking place in the body ove…
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma